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Abstract
The results of research of the Ukrainian Palliative and Hospice Care League show that every year at least 600 
thousand people with incurable illnesses (cancer, HIV/AIDS, diabetes, tuberculosis, and others) need palliative 
care. However, nowadays the realisation of the right to a dignified death for incurable patients is difficult 
because of numerous problems of legislative, organisational, technical, personnel, and moral-ethical nature.
Therapy of chronic pain syndrome is a significant problem for palliative patients in Ukraine, who do not 
receive adequate analgesia. There is non-compliance with the World Health Organisation recommendations 
for pain relief, a strict and complicated legal framework for narcotic medicines and licensing of health 
care facilities (and the reluctance of such establishments to obtain a license), collisions with prescribing of 
opioids, fear of doctors to prescribe high doses of analgesics for patients, and the lack of appropriate skills 
and experience in the treatment of chronic pain in medical specialists. That is why the access of patients 
to analgesic drugs is limited.
However, despite the numerous problems, since 2013 there have been positive changes, in particular, on 
the writing of prescriptions for opioids for palliative care patients.
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WHO — World Health Organisation
PC — palliative care
CPS — chronic pain syndrome 
OA — opioid analgesics
MHU — Ministry of Health of Ukraine
HCF — Health care facility
CMU — Cabinet of Ministers of Ukraine
Introduction
Ukraine is a state located in Eastern Europe, 
which ranks second in the area among other Eu-
ropean countries. According to the State Statistics 
Service, as of January 1, 2019, the population of 
Ukraine is about 42 million people with a morta-
lity rate of more than 600 thousand people each 
year [1].
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The Ukrainian Palliative and Hospice Care League 
in its reports notes that each year more than 600 tho-
usand people in Ukraine need palliative care (PC) 
services. These are patients with circulatory system 
diseases, including chronic heart diseases (almost 
489,000 deaths per year), cancer (100,000), respira-
tory diseases (28,000), tuberculosis (10,000), neurolo-
gical disorders, including Alzheimer’s disease (6500), 
and HIV/AIDS (about 2500) [2].
Patients with incurable diseases, in addition to 
treatment aimed at improving their physical condition, 
also need PC assistance for adequate pain relief and 
improved quality of life that is worsening because of 
symptoms such as dyspnoea, anxiety, and depression. 
However, according to the classification of the World-
wide Hospice Palliative Care Alliance, Ukraine belongs 
to the group of countries “with unsystematic provision 
of PC”. The same status is also attributed to Armenia, 
Cuba, Egypt, Pakistan, Russia, and several other co-
untries, which are similar in their lack of support for 
the palliative movement, the shortage of analgesics 
(in particular morphine), and small number of hospice 
and palliative units [3].
Pain management is an important part of PC. Thus, 
according to World Health Organisation (WHO) data, 
cancer patients need pain relief at all stages of the 
disease. About 80% of patients in the last stage of can-
cer, 50–80% of patients with HIV/AIDS, and 40–70% 
of patients with cardiovascular diseases suffer from 
pain, the intensity of which increases from moderate 
to severe in the later stages of the disease [4–7].
There is a generally accepted (by the world me-
dical community) methodological approach to the 
development of the best clinical practice for the 
control and management of chronic pain syndro-
me (CPS): the WHO three-step “ladder” for cancer 
pain relief. It was developed by a group of experts 
in 1982–1985 and published in 1986 as an official 
document. This “step-by-step” scheme of treatment 
includes analgesic drugs of certain classes (from weak 
to strong) with a gradual dosage increase (titration 
of dose) [8, 9].
The necessity of using opioid analgesics (OA) for 
the treatment of severe pain is shown by international 
clinical recommendations, such as WHO recommen-
dations for cancer pain management [9, 10], clinical 
recommendations of the European Palliative Care As-
sociation on the use of opioids [11, 12], and guidelines 
of National Institute for Health and Care Excellence 
“Palliative care for adults: the use of strong opioids 
for pain relief” [13], and the “Unified clinical protocol 
for palliative care of chronic pain syndrome” of the 
Ministry of Health of Ukraine (MHU) [14]. Neverthe-
less, the availability of opioids for medical purposes 
remains a widespread problem for healthcare systems, 
especially in developing countries, including Ukraine, 
where the level of medical consumption of OA, ac-
cording to the analysis of the International Narcotics 
Control Board, is more than 27 times lower than the 
same one in Germany, and almost twice as in Poland 
(Table 1). However, in comparison with the Russian Fe-
deration and the Republic of Belarus, consumption of 
OA in Ukraine is 5.4 and 1.7 times higher, respectively 
[14]. At the same time, according to the indicator of 
medical consumption of opioids, Ukraine takes 37th 
place in Europe and 59th in the world.
According to the content analysis of literature so-
urces [2, 15–20], the main factors that may affect the 
availability of OA for patients and, as a consequence, 
adequate pain relief in Ukraine can be grouped into 
Table 1. Levels of consumption of narcotic drugs in defined daily doses (DDD) per million inhabitants per day 
in Europe, 2015–2017
Ranking Country 
(top 10)
Total
DDD
Ranking Country 
(down 10)
Total
DDDEuropa Global Europa Global
1 2 Germany 28,862 33 47 Poland 2072
2 4 Austria 21,109 34 48 Cyprus 1944
3 5 Belgium 19,960 35 57 Bosnia and Herzegovina 1123
4 6 Switzerland 19,204 36 58 Romania 1101
5 7 Denmark 17,270 37 59 Ukraine 1067
6 9 Netherlands 16,114 38 67 Belarus 628
7 10 Gibraltar 15,988 39 70 Albania 601
8 13 Spain 13,385 40 71 Republic of Moldova 596
9 14 Iceland 12,955 41 79 Lithuania 410
10 15 United Kingdom 12,575 42 98 Russian Federation 198
Source: Authors’ own development based on [14, 15]
www.journals.viamedica.pl/palliative_medicine_in_practice 189
Sofiya Shunkina et al., Access to opioid analgesics for palliative care patients in Ukraine
Factors influencin 
the availability of OA 
Complicated regulatory acts regarding licensing conditions for the storage and use of 
OA for medical purposes; lack of recognition, evaluation and support of the 
development of the PC system by the government and regional executive authorities
Critically insufficient number of PC facilities, beds and multidisciplinary teams; low -�  
level of development of outpatient service; inaccessibility of PC in rural areas; a low 
number of pharmacies licensed for OA turnover
Inadequate level of training and lack of practical experience in PC; inadequate
assessment of CPS and lack of appropriate skills and experience in the treatment of 
CPS; unwillingness to prescribe an OA because of fears of criminal prosecution
Lack of compliance during the use of medicines (non-compliance with the regimen, 
dosage, etc.); fears of patients and their carers of adverse reactions when using OA 
1) related to 
the state 
regulatory
 policy 
2) organizational
3) asso-
ciated with PC 
experts (including 
non-medical 
specialties)
4) related 
to the physical 
and economic 
availability 
of OA
5) related 
to the patient 
and his family
 members
Lack of adequate state funding for inpatients, low level of patronage and charity; 
limited availability of ambulatory patients with CPS to OA because of big territorial
distances of pharmacies; absence of proper assortment of oral OA, transdermal 
therapeutic systems and other dosage forms; the high cost of OA, the need of 
patients, especially outpatients, to buy them at their own costs
Figure 1. Groups of factors that may affect patients’ access to opioid analgesics. Source: Authors own development 
based on [2, 15–20]
five main groups: organisational, otherfactors linked 
to the state regulatory policy, PC specialists, the phy-
sical and economic availability of OA, and the patient 
and his/her family members (Fig. 1).
Therefore, patients in a hospital, a hospice, a PC 
unit, or a general health care facility (HCF) can obtain 
analgesics from public money (of course, if they are 
available in this facility); morphine, hydromorpho-
ne/hydromorphine, and oxycodone are included in 
the National List of Essential Medicines as OAs for 
the treatment of pain in palliative patients, and they 
may be purchased from budget funds [21]. However, 
according to statistics, the amount of such patients 
is only 10–15%. Most palliative patients in Ukraine 
stay at home, so if they do not receive morphine 
(or other medicines) from HCF or multidisciplinary 
team, then they must buy it in the pharmacy. And 
here the situation looks different. According to the 
Resolution of the Cabinet of Ministers of Ukraine 
(CMU) No. 1303 dated August 17, 1998, patients 
with certain diseases have the right to get medicines 
from a pharmacy free of charge exclusively in the 
case of outpatient treatment of major disease (for 
example, cancer, tuberculosis, HIV/AIDS, diabetes, 
haematological diseases, etc.), for which the patients 
were provided by privileges. Therefore, cancer patients 
can get medicines only for the treatment of cancer, 
but not pain, because pain is just a symptom, not 
a main disease. Only patients with HIV/AIDS have the 
right to receive all medicines free of charge, and so 
they can get painkillers for free.
Access to opioid analgesics: how was it?
The problems of incurable patients, in particular 
qualified inpatient care and the proper provision 
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of OA and care products, have not been considered 
and resolved in Ukraine on national or regional levels 
for a long time. There has been intensive creation of 
a network of palliative medicine units (hospices and 
PC departments in HCF) during the last 15 years. This 
was done mainly because of the initiative of various 
charitable foundations, and public and religious orga-
nisations. Several multidisciplinary teams for provision 
of help to patients at home have been created in 
the last five years. Inpatient PC is provided totally on 
1500 beds, which is just over one third of the needs 
recommended by the WHO. There is no proper care 
system for incurably ill patients at home, although, 
according to the MHU statistics, most of the palliative 
patients (over 80%) die at home without adequate 
pain relief, or social and psychological support [18–20].
In 2010, the Human Rights Watch, together with 
the Institute of Legal Research and Strategies (Kharkiv) 
and the All-Ukrainian Network of People Living with 
HIV/AIDS (regional offices in Rivne and Kyiv) conduc-
ted a study on the presence of pain relief and PC in 
Ukraine. The results were shocking because the main 
practices of PC were largely ignored, and providing 
patients with treatment in accordance with the prin-
ciples of evidence-based medicine was impossible 
due to procedures of fighting with drug addiction. 
That is why analgesics for most patients were practi-
cally inaccessible.
The results of another survey conducted by hu-
man rights organisations show that the expected 
rates of successful pain relief in patients at the level 
of 80–90% of those in need have not yet been achie-
ved. Conditionally successful analgesia is received by 
5–14% of patients only [22]. The main and most signi-
ficant problems with the availability of adequate pain 
control for the patients are listed in the Human Rights 
Watch report [2].
1. Non-compliance with WHO 
recommendations for pain relief, absence of 
oral morphine, and problems with the use of 
opioid analgesics injections.
Despite the WHO recommendations for oral mor-
phine as a gold standard of cancer pain treatment, 
morphine in tablets was not registered in Ukraine 
until 2013, and in oral syrup — until 2016. Doctors 
prescribed injections of strong OA for pain relief. It 
significantly influenced the quality of patients’ lives. In 
addition, due to the legal requirement of admini-
stration of OA injections to patients only by medical 
staff (doctor or nurse), patients did not receive the 
proper amount of the medicines because medical 
personnel were physically unable to visit patients at 
home six times a day (the WHO recommends usage 
of OA every four hours). Patients also suffered from 
an unreasonable limitation of the maximum daily dose 
of injectable morphine (50 mg, equivalent to 150 mg 
of oral morphine), which is noted in the manufac-
turer’s instructions, and it is much lower than the 
dose of morphine recommended by the WHO for 
the effective treatment of severe pain. Because most 
patients need 10-30 mg of oral morphine every four 
hours (60–180 mg per day), even those who are at the 
lowest levels of this typical range need more than the 
maximum recommended daily dose every four hours. 
2. The legal framework for narcotic 
medicines and licensing of HCF.
The procedures for medicine turnover in Ukraine 
are stricter than required by United Nations drug 
conventions, and they contain numerous positions 
that directly inhibit the provision of palliative care. In 
particular, overly onerous bureaucratic requirements 
and fears of negative legal consequences discourage 
doctors from prescribing OA. In accordance with the 
legislation [23], HCF should obtain a license for sto-
rage, prescription, or dispensation of OA. 
However, there are many criteria on the premises 
that must meet requirements before a license can be 
issued. They include a separate storage room for 
narcotic medicines, with certain thickness of walls 
and doors; a fireproof safe attached to the floor; 
the need for a special metal lattice; and for an alarm 
system. The abovementioned requirements are the 
main reason for the limited availability of OA in most 
establishments (both hospitals and pharmacies). The 
situation in rural areas, because often rural health 
posts and small pharmacies do not have separate 
premises for storing OA, is especially critical.
3. Collisions with prescribing opioid 
analgesics for patients.
Until recently, in order to obtain, for example, mor-
phine in ampoules, the patient had to undergo a series 
of bureaucratic stages that delayed the process of pain 
relief. These are, in particular: an examination by the 
oncologist and his/her conclusion about the prescri-
bing of OA; a session of a medical commission (at least 
three doctors) and approval of its conclusion; appro-
val of the conclusion by the chief doctor of the HCF; 
a record in the form of a medication administration 
card about the new patient’s medicines (or a special 
prescription written by the doctor if the patient will 
purchase medicines at the pharmacy at his/her own 
expense); receiving OA from a nurse in a hospital and 
visiting a patient at home for drug administration (or 
purchase of a medicine by the patient or his/her carer 
at the pharmacy according to special prescription and 
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usage of it without a medical worker’s assistance) 
(requirements according to the Order of the MHU No. 
11 dated January 21, 2010, cancelled for today). It 
should also be noted that very often doctors refused to 
prescribe OA, explaining this either by the absence of 
prescription forms or strict prescription requirements, 
or the fear of potential drug addiction. Another barrier 
that significantly complicated receiving OA by patients 
was the strict accounting of unused or empty ampo-
ules in the case when the patient did not purchase 
the medicine at his/her own expense (and this is the 
majority of patients). Thus, in accordance with the 
requirements of the legislation (no longer valid Order 
of the MHU No. 11 dated January 21, 2010), the me-
dical staff who directly visits the patient should record 
each operation in separate journals (during receipt of 
the medicine, when the drug is administered, when 
the ampoules are returned, etc.), as well as to collect 
empty and unused ampoules, which are then the sub-
ject to disposal procedures. All these factors together 
have led to unjustified inhuman suffering of patients.
4. Education and knowledge of medical 
specialists in the principles of providing PC; 
in particular, pain treatment.
Pharmacotherapy of pain in terminal patients is 
studied by students of higher medical institutions in 
Ukraine very fragmentarily when studying different 
disciplines, and doctors and medical staff need the-
oretical knowledge and practical skills from different 
aspects of the PC [15]. Some issues of PC are studied 
in the process of training nurses at the Andriy Kru-
pynsky Lviv State Medical College, I.V. Radziyevska 
Cherkassy Basic Medical College, and Nursing School 
of I. Gorbachevsky Ternopil National Medical University 
[24]. Also, in Ukraine there is no proper postgradu-
ate education system for doctors and nurses – only 
two medical universities in Kyiv and Ivano-Frankivsk, 
as well as Cherkassy Basic Medical College, have PC 
topics included in the study cycles of doctors and 
nurses. In fact, doctors and nurses who work in the PC 
study by themselves by visiting different conferences, 
seminars, and other information events, mostly orga-
nised by nongovernmental organisations supported 
by the MHU.
Accessibility of opioid analgesics: what 
has changed in the legislation?
During the second half of the 20th century in Ukra-
ine, because of fears about the spread of drug addic-
tion, the regulatory requirements for the control of 
narcotic substances were intensified. Also, there were 
contradictory positions in these documents for a long 
time. Thus, domestic experts found a sharp decrease 
in the use of morphine hydrochloride for medical 
purposes following the entry into force of the Order 
of the MHU No. 356 dated December 18, 1997 [15].
The turning point for national legislation was 
2013, when, thanks to the active cooperation of 
public organisations and the MHU, the Ministry of 
Internal Affairs of Ukraine, and the State Service 
of Ukraine on Medicines and Drugs Control, CMU 
Decree No. 333 dated May 13, 2013 was adopted. 
In the same year, oral morphine (immediate-release 
tablets of 5 and 10 mg) was first registered in Ukraine 
[25]. That was a significant breakthrough in domestic 
pain therapy, and it became another reason for the 
revision and adjustment of domestic legislation. The 
appearance of oral forms of OA in Ukraine and CMU 
Decree No. 333 greatly expanded the possibility of 
conducting adequate analgesic therapy for patients 
with CPS. The procedure of turnover of OA used for 
the treatment of CPS in Ukraine is regulated by the 
following normative and legal acts:
1. Law of Ukraine “About narcotic drugs, psycho-
tropic substances, and precursors” No. 61/95-VR 
dated February 15, 1995 [26].
2. Resolution of CMU No. 770 dated May 6, 2000 
“About approval of the list of narcotic drugs, 
psychotropic substances, and precursors” [27].
3. Order of MHU No. 360 dated July 19, 2005 “About 
approval of the rules for writing of prescriptions 
and requirements-orders for medicines and me-
dical products, the procedure for the dispensing 
of medicines and medical products from pharma-
cies and their structural subdivisions, instructions 
on the procedure for storage, accounting, and 
destruction of prescriptions and requirements-or-
ders” [28].
4. Resolution of CMU No. 589 dated June 3, 2009 
“About approval of the procedure for the activities 
of the circulation of narcotic drugs, psychotropic 
substances and precursors, and the control over 
their turnover” [29].
5. Resolution of CMU No. 333 dated May 13, 2013 
“About approval of the procedure for the purcha-
se, transportation, storage, dispensing, usage, 
and destruction of narcotic drugs, psychotropic 
substances, and precursors in health care institu-
tions” [30].
6. Order of MHU No. 494 dated August 7, 2015 “Abo-
ut some issues of purchase, transportation, stora-
ge, dispensing, usage, and destruction of narcotic 
drugs, psychotropic substances, and precursors in 
health care facilities” [31], instead of order of MHU 
No. 11 dated January 21, 2010 “About approval of 
the procedure for the turnover of narcotic drugs, 
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Table 2. The main common and distinct aspects in the issues of opioid analgesics turnover in normative documents
No. Issues of OA 
turnover
Resolution of CMU  
No. 333 dated May 13, 2013 
(currently valid)
Order of MHU 
No. 11 dated January 21, 2010 
(invalid from September 22, 2015)
Order of MHU 
No. 494 dated August 7, 2015 
(currently valid)
1 Activity on 
turnover
It is carried out by HCF of all forms of ownership
2 Storage of OA They are stored in premises that are in compliance with the requirements of the Ministry of 
Internal Affairs for the objects and premises intended for carrying out activity related to OA 
turnover; keys from safes, metal cabinets and premises in which OA are stored, and sealing 
devices (if any) are kept by the responsible persons
3 Storage volu-
me of OA in 
the pharmacy
OA are stored in a storage room in volumes 
not exceeding the pharmacy’s 3-month 
needs; in the manufacturing (pharmacist 
technician) room OA are stored in an amo-
unt that does not exceed their daily need, 
necessary for the production of medicines
This is not indicated
4 Storage volu-
me of OA in 
the HCF
Storage volume of OA in the HCF should 
be no more than a 1-month need, and in 
the office (post) — no more than 7-day 
requirements
Storage volume of OA in the HCF should be 
no more than a 2-week need, and in the office 
(post) — no more than 1-day need, and on 
weekend (festive) days — 3-day need
The volume of storage of OA for the following 
month (Km) in hospices, PC departments, 
and health care institutions that provide PC is 
calculated by the formula: Km = (K1 + K2 + 
K3 ... + Kn) × D × 1.25, where K1, K2, K3 ... 
Kn - quantity of OA per day, intended for 1, 
2, 3, and n patients at the time of calculation 
of storage volumes; D — number of days in a 
month
psychotropic substances and precursors in health 
care facilities of Ukraine” [32].
Until 2015, the Order of MHU No. 11 was in force 
in Ukraine, which significantly restricted the prescri-
bing of OA to patients. The main differences between 
Order No. 11 and the new valid normative documents 
(Resolution of CMU No. 333 and Order of MHU No. 
494) are given in Table 2.
As can be seen from the data in Table 2, on some 
issues the Resolution of CMU No. 333 and the Order 
of MHU No. 11, which were in force during the same 
period of 2013–2015, contradicted each other, for 
example, in the storage volumes of OA in HCF, and 
also in the order of prescribing of OA to patients. With 
the cancellation of the Order of the MHU No. 11 the 
procedure for prescribing OA to patients was sub-
stantially facilitated: if previously the decision on the 
prescribing of an OA to patient for more than three 
days had to be taken by the commission of the HCF, 
now, regardless of the term of appointment, this is 
done only by the patient’s doctor. It is also substan-
tially facilitated that the administration of parenteral 
forms of OA may be carried out by a carer or family 
member of the patient, and not necessarily only by the 
medical staff of the health care institution where the 
OA has been prescribed. Significant progress is seen 
in the cancellation of the disposal of empty ampoules 
and blisters after using OA. Now only unused OA that 
have been received by the patient or his/her carer at 
a health care facility are disposed of. Doctors have 
the right to prescribe opioids for a 15-day course of 
treatment, indicating this on the prescription form, 
for PC patients at home.
In recent years, in particular since 2013, the rules 
for prescribing OA have changed significantly. A com-
parison of changes in prescribing OA for palliative 
patients is presented in Table 3. Thus, a significant 
simplification for patients was the cancellation of the 
maximum dose of dispensing OA on one prescription, 
as well as the cancellation of pharmacy attachment 
to a health care institution in one administrative unit 
(region, city, village, etc.). This means the possibility 
of purchasing drugs for a 15-day course of treatment 
in any pharmacy in Ukraine (which has an appropriate 
license) regardless of the institution where the pre-
scription was written.
Æ
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No. Issues of OA 
turnover
Resolution of CMU  
No. 333 dated May 13, 2013 
(currently valid)
Order of MHU 
No. 11 dated January 21, 2010 
(invalid from September 22, 2015)
Order of MHU 
No. 494 dated August 7, 2015 
(currently valid)
5 A document 
for accounting 
of OA
Special form of Journal defined by the 
MHU
Special form of Journal 129–8/o
The pages of the journal are numbered, bound, and sealed by stamp of the health care 
institution and the signature of the chief doctor
6 The procedure 
for the appo-
intment of OA 
to palliative 
inpatients
OA are prescribed by doctors or medical 
assistants (paramedics) in accordance 
with the medical indications defined by 
the MHU; the appointment of OA to the 
patient for a period of more than 10 days 
is carried out by a doctor with a compul-
sory justification for the need for further 
use of OA, which is noted in the patient’s 
medical card
OA are appointed by doctors of HCF in accor-
dance with medical indications; the decision 
to appoint OA to patient for a period of more 
than 3 days is made by the special medical 
commission with the mandatory approval of 
this decision by the chief doctor or his/her 
deputy on medical work
7 The procedure 
for the appo-
intment of OA 
to palliative 
outpatients
Outpatients are provided with OA by 
HCF or by prescription in pharmacies at 
volumes not exceeding the 15-day need; 
the doctor who prescribes OA is obligated 
to inform the patient or the person caring 
for him/her (family member, guardian, or 
trustee) about the rules of handling OA, 
prohibition of their use not for medical 
purposes, and giving the patient or his/her 
carer a special information sheet. All of this 
should be noted in the medical card of the 
patient
Outpatients should be provided with OA by 
the HCF only at the place of their residence; 
administration of parenteral forms of OA at 
home should be carried out only by medical 
workers, in particular, the medical staff of the 
outpatient clinics, the paramedic and obstetric 
stations (rural health posts) at the place of 
residence of the patient, with a mandatory 
record about that in the medical card of the 
patient
8 The order of 
the destruc-
tion of empty 
ampoules and 
blisters from 
the used OA 
in the health 
care institu-
tion.
There is no particular procedure for de-
struction of empty ampoules or blisters; 
Only the mechanism of the returning to 
HCF of unused OA is defined, they should 
be subsequently destroyed in accordance 
with the procedure established by the law
Every day, except for weekends and holidays, 
empty ampoules from used OA should be 
returned to the materially responsible persons 
to the commission. The destruction of empty 
ampoules from the used OA should be carried 
out at least once in 10 calendar days, imme-
diately after that the act on the destruction 
must be drawn up and signed by all members 
of the commission
The order of 
returning of 
unused OA
This is not indicated Empty ampoules and blisters from used OA do 
not require additional quantitative accounting 
and a particular destruction procedure.
If OA were received at the health care institu-
tions, a family member or carer must return 
unused medicines to the doctor (paramedic) 
who had prescribed OA or to the responsible 
person who delivered them to the patient.
If OA were received by prescription at the 
pharmacy, a family member or carer must 
ensure disposal of OA 
9 Inventory 
check
After the end of the current month, materially responsible persons are obliged to check the 
actual quantity of OA with their quantity according to records in the accounting journal. It 
should be done on the first day of the next month.
If the actual presence of OA is in deviation with that indicated in the accounting journal, the 
health care institution is obligated within 3 calendar days to carry out an inventory check of 
OA, which is listed by this materially responsible person. The procedure of such an inventory 
is determined by the legislation
Source: Authors’ own development
Table 2 cont. The main common and distinct aspects in the issues of opioid analgesics turnover in normative documents
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Table 3. Prescribing of opioid analgesics to palliative patients (Order of MHU No. 360 dated July 19, 2005)
Aspect of the Order Features of prescribing the OA
in edition until 2013 in edition since 2013
Who  
has the right to write a pre-
scription?
Doctor (physician)
– A medical assistant (paramedic) (for pa-
tients with protracted and chronic diseases 
in case of continuation of the treatment 
course by the doctor)
The form  
of the prescription
A special blank of pink colour (F–3)  
for narcotic and psychotropic medicines is needed
Since 2019 there has been an electronic 
recipe. It should be filed with an electronic 
signature of a healthcare worker in accor-
dance with the legislation on electronic 
document circulation and electronic trust 
services
The prescription is valid for 5 days 10 days
Name of the medicine Trade name International non-proprietary name (INN)
The maximum amount of OA 
that can be prescribed and 
dispensed to a palliative pa-
tient on one prescription (on 
an example of morphine)
Tablets 5 mg — 20 tablets
Tablets 10 mg — 10 tablets
Ampoules 1% 1 mL — 10 ampoules
In one prescription OA in the amount for 
a 15-day course of treatment may be pre-
scribed (the daily dose of OA is calculated 
by the doctor based on the intensity of the 
pain and the patient’s relief)
Peculiarities of the prescrip-
tion requisites
There must be a signature and 
personal seal of the doctor, a round 
seal of the health care institution, the 
signature of the chief doctor or his/
her deputy on the medical work
Since 2017 the signature and personal seal 
of the doctor, special marks such as «For a 
chronic patient», are additionally certified 
by a signature and personal seal of the 
doctor
Place of purchase of OA on a 
special prescription
These are pharmacies licensed for acti-
vities on turnover of narcotic drugs 
and psychotropic substances. They 
are located in one administrative-ter-
ritorial unit (city, district, and region) 
with a health care institution and 
are attached to it by the order of the 
appropriate health care department 
of the local state administration
These are pharmacies licensed for activities 
on turnover of narcotic drugs and psycho-
tropic substances
Source: Authors’ own development
Pharmacies
Physical accessibility of patients to OA is important. 
It is provided by a sufficient number of pharmacies 
appropriately licensed for this activity. Unfortunately, 
Ukraine has a poorly developed pharmacy network to 
provide the population with OA, especially in rural 
areas [15].
According to data of teh State Service of Ukraine 
on Medicines and Drugs Control of Ukraine, as of 
2019 only 2% (518 out of 22,980) pharmacies have 
a license for the dispensing of controlled medici-
nes (narcotic medicines, psychotropic substances, 
and precursors). The majority of such pharmacies 
(406 pharmacies or 78.8%) are located in cities. At the 
same time, 457 pharmacies (88%) are of communal 
property. The largest numbers of such pharmacies 
are in the western and northern parts of the country 
(119 and 107, respectively) while in southern and 
eastern Ukraine there are half as many (47 and 55, 
respectively). On average, in our country, for one 
pharmacy that dispense OA, there are 81,578 people. 
In other countries, this number is 20–46 times lower: 
in Latvia — 2560, in Poland — 2300, in Slovakia 
— 2570, in Bulgaria — 1753, and the Czech Republic 
— 4015 people. It should be noted that in Latvia, Po-
land, and Slovakia, all pharmacies without exception 
must have and dispense a full range of medicines [33]. 
Current key issues
Despite the presence in Ukraine of various forms 
of OA (injections, pills, and syrups), many patients 
with severe illnesses and chronic pain do not have 
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access to adequate pain treatment. This is regularly 
documented by representatives of human rights or-
ganisations. Contemporary key problems in providing 
patients with OA are:
1. The absence of a national strategy/program for 
the medical provision of the population with OA. 
Such a strategy should include clear rules for pre-
scribing, dispensing, administering (including the 
algorithm for providing the necessary number of 
procedures, such as parenteral administration, to 
each patient), recording, storing, and disposing of 
these medicines. It should also ensure registration 
of necessary medicines that are not available on 
the domestic market (for example, oral morphine 
until 2013) in the short term. Such a strategy sho-
uld include reimbursement. It is expedient that the 
state promotes inclusion of OA into the assortment 
of pharmacies through tax breaks, subsidies, etc. 
2. The inconsistency and excessive severity of domestic 
legislation on the licensing and turnover of narcotic 
analgesics. Also, there is a problem with a long bure-
aucratic procedure for the prescription of these drugs.
3. Insufficient provision of population access to phar-
macies that dispense OA (more than 81 thousand 
people served by one such pharmacy). The acces-
sibility of such medicines for the population is 
especially problematic in rural areas (only one from 
all the pharmacies (518) is located there). 
4. Incompleteness in coverage of the problem of 
chronic pain pharmacotherapy in terminal patients 
in programs of higher and secondary medical 
educational institutions of Ukraine. This leads to 
low awareness and competence of future doctors 
and nurses in this area.
That is why measures regarding regulations of cu-
rrent legislation on circulation of OA, and of projects 
on Higher Education Standards for student training 
and postgraduate retraining of doctors, paramedics, 
nurses, and social workers on palliative care are pro-
posed by the “State Narcotic Drug Policy Strategy 
for the period up to 2020”. Approval of medical and 
technological documents on providing palliative care, 
treatment of pain syndrome in children and adults, 
and substitution maintenance therapy is also neces-
sary, as well as national assessment of OA needs, 
promoting of the expansion of the network of phar-
macies that are licensed for activities on OA turnover, 
improving accessibility of OA, and implementation of 
state regulation of OA prices [34].
Conclusions
1. Palliative care in Ukraine requires optimisation be-
cause of its insufficient provision in hospitals (1500 
beds is one third of the number recommended by 
the WHO), and the lack of a proper care system 
for incurably ill patients at home. The inadequate 
level of medical personnel competence, the lack 
of patient compliance with treatment plans, and 
the negative effect of the economic component 
of treatment (lack of public funding and reimbur-
sement) should be emphasised too.
2. The problems of domestic medicine in providing 
patients with OA are systemic and are due to the 
lack of a state strategy/program for the develop-
ment of this sector of medicine and pharmacy. 
There are also issues with the insufficient number 
of pharmacy establishments having an appropria-
te license, too stringent legislative conditions for 
obtaining a license and conducting such acti-
vities by pharmacies, and incomplete assortment 
of these medicines (no therapeutic transdermal 
systems). 
3. A detailed chronological analysis of the legislative 
framework on OA turnover in Ukraine over the past 
20 years has been carried out. Since 2013 there 
have been positive changes, in particular regarding 
the writing of prescriptions on OA for palliative 
patients: the maximum dose of dispensing OA on 
one prescription and the local attachment of a 
pharmacy to HCF have been cancelled.
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